Business Wire

BONA

Share
Announcing the Launch of Bona Mega EVO™

Bona, a global, sustainably driven company that supplies products for installing, renovating, maintaining, and restoring premium floors, is announcing the launch of its new lacquer, Bona Mega EVO™. This next generation lacquer offers a new state-of-the-art crosslinking technology that activates when applied. The unique, non-yellowing formula delivers faster curing with excellent resistance to scratches, wear, and chemicals. With VOC levels below 3%, the lacquer contributes to healthier working conditions with a lower impact on indoor air quality.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240114100435/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Announcing Bona Mega EVO™ a next generation lacquer that offers new state-of-the-art crosslinking technology that activates when applied. The unique, non-yellowing formula delivers faster curing with excellent resistance to scratches, wear, and chemicals. With VOC levels below 3%, Bona Mega EVO contributes to healthier working conditions with a lower impact on indoor air quality. (Photo: Business Wire)

Bona Mega EVO™ is the next evolution of Bona Mega, which was first introduced in 1996 and offered an industry-first oxygen crosslinking technology and, at the time, was considered a top choice among flooring contractors for use as a one-component topcoat for wood floors in environments requiring medium to light commercial wear resistance. Bona Mega EVO™ is the next generation that incorporates a completely new and significantly faster technology that is unique to Bona. The self crosslinking occurs entirely within the lacquer without the use of any external components, making it a next generation coating.

“When it comes to performance, Bona Mega EVO™ is an advancement in every way. With the new self crosslinking technology, we have merged the top features from Bona Mega and Bona Mega ONE to create an exceptional product. It stands out from the competition due to its consistently high level of performance. Bona Mega EVO™ is the next step for coating medium- to light-commercial areas and domestic wood floors,” said Thomas Hallberg, Director Product Management Professional EMEA/APAC, Bona AB

Bona Mega EVO’s new self crosslinking technology provides a topcoat that dries quickly, remains clear over time, offers excellent sanding ability, and has VOC levels below 3%. It has high filling abilities, low odour, and excellent scratch, wear, and chemical resistance. With Bona Mega EVO’s fast-drying and quick cure time, the floor can be in use more quickly when compared to other one-component lacquers. This also means that the next topcoat layer can be applied much sooner than with traditional polymer technology.

Bona Mega EVO™ guarantees a uniform colouring of the wood floor even without the use of a primer making it possible to use just one product during the whole process. It has a non-yellowing formula with minimal odour during the application process and dissipates rapidly afterwards.

With VOC levels below 3%, Bona Mega EVO™ fulfills the EMICODE® EC1PLUS certification. Bona continues its work to phase out PFAS, of which Bona Mega EVO is no exception, promoting a safer environment.

About Bona

Bona is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. The head office is in Malmö, Sweden, and the company is represented globally across 90 countries through 16 subsidiaries, 70 distributors, 4 production sites and over 600 employees. For more visit www.bona.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240114100435/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye